Competing immune biomarkers in the selection of first-line therapy in non-small cell lung cancer

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)67-69
Number of pages3
JournalEuropean Oncology and Haematology
Volume14
Issue number2
StatePublished - Jan 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Biomarkers
Therapeutics
pembrolizumab

Keywords

  • Combination therapy
  • Immuno-chemotherapy
  • Non-small cell lung cancer
  • PD-L1
  • Pembrolizumab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Competing immune biomarkers in the selection of first-line therapy in non-small cell lung cancer. / Tolba, Khaled.

In: European Oncology and Haematology, Vol. 14, No. 2, 01.01.2018, p. 67-69.

Research output: Contribution to journalComment/debate

@article{67e65d1e74064d23a10d2232636c11e4,
title = "Competing immune biomarkers in the selection of first-line therapy in non-small cell lung cancer",
keywords = "Combination therapy, Immuno-chemotherapy, Non-small cell lung cancer, PD-L1, Pembrolizumab",
author = "Khaled Tolba",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
volume = "14",
pages = "67--69",
journal = "European Oncology and Haematology",
issn = "2045-5275",
publisher = "Touch Digital Media",
number = "2",

}

TY - JOUR

T1 - Competing immune biomarkers in the selection of first-line therapy in non-small cell lung cancer

AU - Tolba, Khaled

PY - 2018/1/1

Y1 - 2018/1/1

KW - Combination therapy

KW - Immuno-chemotherapy

KW - Non-small cell lung cancer

KW - PD-L1

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85057823320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057823320&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:85057823320

VL - 14

SP - 67

EP - 69

JO - European Oncology and Haematology

JF - European Oncology and Haematology

SN - 2045-5275

IS - 2

ER -